Plasma Ceruloplasmin Ferroxidase Activity Correlates with the Nigral Sonographic Area in Parkinson’s Disease Patients: A Pilot Study

[1]  S. Rivera-Mancía,et al.  The transition metals copper and iron in neurodegenerative diseases. , 2010, Chemico-biological interactions.

[2]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[3]  Ping-Keung Yip,et al.  Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism , 2007, Journal of Neurology.

[4]  D. Dressler,et al.  Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[5]  D. Berg,et al.  Predictive value of transcranial sonography in the diagnosis of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[6]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage , 2006, Journal of Neural Transmission.

[7]  D. Berg,et al.  Application of Transcranial Sonography in Extrapyramidal Disorders: Updated Recommendations , 2006, Ultraschall in der Medizin.

[8]  R. Krüger,et al.  The FASEB Journal express article 10.1096/fj.04-3486fje. Published online September 8, 2005. Functional relevance of ceruloplasmin mutations in Parkinson’s Disease , 2022 .

[9]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[10]  D. Dressler,et al.  Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy , 2004, Neurology.

[11]  B U Meyer,et al.  Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes , 2002, Neurology.

[12]  R. Benecke,et al.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.

[13]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[14]  C. Tanner,et al.  Epidemiology of Parkinson's disease and akinetic syndromes , 2000, Current opinion in neurology.

[15]  J. Snaedal,et al.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. , 1999, Pharmacology & toxicology.

[16]  T. Kawanami,et al.  Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain , 1999, Neurology.

[17]  C. Ríos,et al.  Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease , 1999, Neuroscience Letters.

[18]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[19]  A. Schapira.  OXIDATIVE STRESS IN PARKINSONS-DISEASE , 1995 .

[20]  D R Rajput,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[21]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[22]  T. Imanari,et al.  A new method for assay of ferroxidase activity and its application to human and rabbit sera. , 1984, Chemical & pharmaceutical bulletin.

[23]  C. Zhong,et al.  Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. , 2011, Brain : a journal of neurology.

[24]  D. Berg,et al.  Brain iron pathways and their relevance to Parkinson's disease. , 2001, Journal of neurochemistry.

[25]  A. Rajput,et al.  Progressive Supranuclear Palsy , 2001, Drugs & aging.